搜尋結果
BioNTech has significant expertise in incorporating naturally occurring modified nucleosides into our therapeutic mRNAs. We have demonstrated that incorporating a variety of modified nucleosides in the manufactured mRNA suppresses its intrinsic immune activation, while leading to superior protein production over time.
2022年4月1日 · 輝瑞/Bio NTech屬於合成疫苗,採用信使核糖核酸(mRNA)技術,簡單說就是用病毒遺傳物質注入人體,導致人體細胞生成病毒刺突蛋白,激活人體免疫 ...
辉瑞-BioNTech 2019冠状病毒病疫苗[5] (英語: Pfizer–BioNTech COVID-19 vaccine,簡稱: 輝瑞BNT疫苗 、 輝瑞疫苗 、 BNT疫苗[4],代號: BNT162b2, 商品名: Comirnaty[2] 、 復必泰, 國際非專利藥品名稱:tozinameran [1]),是一種專門對抗 严重急性呼吸系统综合征冠状病毒2 ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
2022年4月1日 · 据路透社报道,中国唯一进入三期临床试验的mRNA候选疫苗是ARCoV,由中国军事科学院、苏州艾博生物科技有限公司、云南沃森生物技术股份有限公司 ...
2024年8月16日 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.
2021年1月25日 · 食物及衞生局局長今日(一月二十五日)根據《預防及控制疾病(使用疫苗)規例》(第599K章)(《規例》),認可復星醫藥/德國藥廠BioNTech的新冠疫苗(即Comirnaty COVID-19 mRNA Vaccine(BNT162b2)Concentrate for Dispersion for Injection)在香港作緊急使用。. 根據 ...